Analysts Clash on Bayer’s Next Move After a Historic Legal Win
29.06.2026 - 17:35:13 | boerse-global.de
The U.S. Supreme Court’s June 25 ruling—a 7–2 decision barring states from mandating cancer warnings on glyphosate products—sent Bayer shares soaring more than 22% in a single week. By Friday, the stock had closed at €46.61, within striking distance of its 52-week high of €49.93. But the euphoria masks a sharp divide among sell-side analysts about what the verdict actually means for the company’s future.
Three houses updated their ratings within days, and their conclusions could hardly be more divergent. DZ Bank raised its fair value to €54 from €51 and kept a “Buy” rating, with analyst Peter Spengler calling the ruling a fundamental shift in the litigation risk profile. Goldman Sachs also reaffirmed “Buy” with a €55 target, arguing that current valuations already discount legal overhangs and high debt, but that pharma pipeline potential and a planned refocusing offer upside. Jefferies was far more cautious: it lifted its target to €46 from €40 but held at “Hold,” noting that while the decision limits failure-to-warn claims, it does little to alter the ongoing class-action settlement process.
That process now pivots to a courtroom in St. Louis. On July 9, a fairness hearing will examine the proposed $7.25 billion settlement meant to resolve existing and future glyphosate lawsuits. If the judge approves the deal, Bayer gains legal clarity on the largest batch of claims. If it stalls, the company’s debt reduction plans hit a wall. Even after the Supreme Court victory, plaintiff lawyers are already exploring alternative legal theories, meaning the chapter is far from closed.
Should investors sell immediately? Or is it worth buying Bayer?
The balance sheet remains the most stubborn challenge. Net financial debt stood at roughly €33 billion as of late March, and first-quarter settlement payouts alone consumed about €2 billion. For the full year, management expects around €5 billion in litigation costs, which will likely push free cash flow into negative territory—as low as minus €2.5 billion. That cash burn constrains the ability to invest in growth, regardless of the legal headline.
Operationally, however, there are signs of a turnaround. A new organizational model is expected to save €2 billion annually starting this year. The Crop Science division is already improving margins, while Pharmaceuticals targets mid-single-digit growth from 2027 onward. By 2030, Bayer’s operating margin could approach 30%, boosted by new oncology and cardiology products. CEO Bill Anderson has repeatedly left the door open to portfolio divestitures, though no formal breakup is on the table.
The stock’s rally has not gone unnoticed by technical traders. The relative strength index now stands at 80.6—well into overbought territory—suggesting profit-taking could be imminent. On a 12-month basis, shares have still gained roughly 82%, but the short-term risk of a pullback is real.
Investors will get their next hard data point on August 7, when Bayer reports second-quarter results. The company had previously guided for stable revenue and mid-single-digit EBITDA growth before special items. Whether management upgrades that outlook after the Supreme Court ruling will be the key question during the analyst call. Combined with the outcome of the St. Louis hearing, the next six weeks will determine whether Bayer’s legal victory translates into a sustainable rerating—or fades into another chapter of balance-sheet strain.
Ad
Bayer Stock: New Analysis - 29 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
